Illinois HB4834 amends the Illinois Controlled Substances Act to exempt testosterone, mifepristone, misoprostol, GnRH analogues, and estrogen from.
HB4834 amends the Illinois Controlled Substances Act by modifying the Prescription Monitoring Program to exclude testosterone, mifepristone, misoprostol, GnRH analogues, and estrogen from its purview. The Department of Human Services is mandated to purge all existing records related to these substances from the Prescription Monitoring Program by January 1, 2027. The bill also outlines specific information that dispensers must transmit to the central repository for controlled substances, including patient details and prescription specifics.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.